Wednesday, October 24, 2018 11:26:23 AM
vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 9, 2018-- vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary efficacy endpoint. Patients taking azeliragon compared with placebo did not improve in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb).
IN JUNE 2018
View printer-friendly version
<< Back
vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.
+++++++++++++++++++++++++
However, consistent with findings in Part A and the Phase 2b trial, lower maximal plasma concentrations of azeliragon in Part B were associated with improvements in efficacy relative to placebo.
“We are eager to obtain early feedback from the FDA based on the results we have achieved and the data that we have observed associating lower plasma levels of the drug and improved efficacy,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “As a result, we believe that azeliragon has the potential to address the pressing unmet need in Alzheimer’s disease.”
While in April and in June 2018 topline results were announced that the A-Study and the B-Study did not meet the co-primary endpoints and clinical trials were ended, subsequent post-hoc subgroup analyses have shown populations that experienced positive benefits.
SO WE ARE WAITING FOR THE RESULTS OF THESE SUB-GROUP
Recent VTVT News
- vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 08:51:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:32:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:28:15 PM
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT • PR Newswire (US) • 03/19/2024 12:30:00 PM
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:47:37 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/06/2024 12:52:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:04:31 PM
- vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:26:55 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:14:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:08:30 PM
- vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE • PR Newswire (US) • 02/22/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:26:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:28:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:21:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:23:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:22:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:19:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:31 PM
- vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 09:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM